Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 49 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Christodoulou, Christos  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
O
Lazaridis, G., Kotoula V., Vrettou E., Kostopoulos I., Manousou K., Papadopoulou K., et al. (2019).  Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer.. Cancer Genomics Proteomics. 16(3), 195-206.
P
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Stavropoulou, A. V., Fostira F., Pertesi M., Tsitlaidou M., Voutsinas G. E., Triantafyllidou O., et al. (2013).  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.. PLoS One. 8(3), e58182.
Economopoulou, P., Kotoula V., Koliou G-A., Papadopoulou K., Christodoulou C., Pentheroudakis G., et al. (2019).  Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.. Transl Oncol. 12(5), 739-748.
Koletsa, T., Kotoula V., Koliou G-A., Manousou K., Chrisafi S., Zagouri F., et al. (2020).  Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunol Immunother.
Fountzilas, E., Kotoula V., Pentheroudakis G., Manousou K., Polychronidou G., Vrettou E., et al. (2019).  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer.. ESMO Open. 4(2), e000474.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Fountzilas, E., Kotoula V., Tikas I., Manousou K., Papadopoulou K., Poulios C., et al. (2018).  Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer.. Oncotarget. 9(86), 35623-35638.
Bamias, A., Karadimou A., Lampaki S., Lainakis G., Malettou L., Timotheadou E., et al. (2010).  Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.. BMC Cancer. 10, 45.
Strati, T-M., Kotoula V., Kostopoulos I., Manousou K., Papadimitriou C., Lazaridis G., et al. (2017).  Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.. Anticancer Res. 37(5), 2323-2334.
Zagouri, F., Kotoula V., Kouvatseas G., Sotiropoulou M., Koletsa T., Gavressea T., et al. (2017).  Protein expression patterns of cell cycle regulators in operable breast cancer.. PLoS One. 12(8), e0180489.
R
Bafaloukos, D., Linardou H., Aravantinos G., Papadimitriou C., Bamias A., Fountzilas G., et al. (2010).  A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.. BMC Med. 8, 3.
Kotoula, V., Tsakiri K., Koliou G-A., Lazaridis G., Papadopoulou K., Giannoulatou E., et al. (2019).  Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.. Clin Breast Cancer. 19(2), 113-125.e4.
Razis, E., Kalogeras K. T., Kotsantis I., Koliou G-A., Manousou K., Wirtz R., et al. (2020).  The Role of CXCL13 and CXCL9 in Early Breast Cancer.. Clin Breast Cancer. 20(1), e36-e53.
S
Papaxoinis, G., Kotoula V., Alexopoulou Z., Kalogeras K. T., Zagouri F., Timotheadou E., et al. (2015).  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.. PLoS One. 10(10), e0140293.
Pentheroudakis, G., Kotoula V., Fountzilas E., Kouvatseas G., Basdanis G., Xanthakis I., et al. (2014).  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).. BMC Cancer. 14, 111.
T
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
Christodoulou, C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., et al. (2009).  Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.. Oncology. 76(4), 275-85.
Koutsoukos, K., Tzannis K., Christodoulou C., Karavasilis V., Bakoyiannis C., Makatsoris T., et al. (2015).  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).. World J Urol.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές